Homepage Top Section2

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to

Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia. The agreement grants Knight

Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the

The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that

The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the

The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial

The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The